Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Anti-diabetic drugs
Empagliflozin/metformin
Другие языки:

    Empagliflozin/metformin

    Подписчиков: 0, рейтинг: 0

    Empagliflozin/metformin
    Combination of
    Empagliflozin SGLT2 inhibitor
    Metformin Hydrochloride Anti-diabetic biguanide
    Clinical data
    Trade names Synjardy, Jardiamet
    AHFS/Drugs.com Professional Drug Facts
    License data
    Pregnancy
    category
    • AU: D
    Routes of
    administration    		 By mouth
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
    • UK: POM (Prescription only)
    • US: ℞-only
    • EU: Rx-only
    Identifiers
    CAS Number
    PubChem CID
    UNII
    KEGG
    ChEBI
    Chemical and physical data
    Formula C27H39Cl2N5O7
    Molar mass 616.54 g·mol−1
    3D model (JSmol)
    • CN(C)C(=N)N=C(N)N.COC1C(C(C(C(O1)C2=CC(=C(C=C2)Cl)CC3=CC=C(C=C3)OC4CCOC4)O)O)O.Cl
    • InChI=1S/C23H27ClO7.C4H11N5.ClH/c1-28-23-21(27)19(25)20(26)22(31-23)14-4-7-18(24)15(11-14)10-13-2-5-16(6-3-13)30-17-8-9-29-12-17;1-9(2)4(7)8-3(5)6;/h2-7,11,17,19-23,25-27H,8-10,12H2,1H3;1-2H3,(H5,5,6,7,8);1H/t17-,19+,20+,21-,22-,23-;;/m0../s1
    • Key:YBRWIMHXUHRVDV-ZBYKXHQASA-N

    Empagliflozin/metformin, sold under the brand name Synjardy among others, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It contains empagliflozin and metformin hydrochloride. It is taken by mouth.

    The most common side effects include hypoglycaemia (low blood sugar levels) when the medicine is taken with a sulphonylurea or insulin, infections of the urinary tract and genitals, and increased urination.

    It was approved for use in the European Union in May 2015, for use in the United States in August 2015, and for use in Australia in May 2020. In 2020, it was the 238th most commonly prescribed medication in the United States, with more than 1 million prescriptions. It is available as a generic medication.

    Medical uses

    In the European Union empagliflozin/metformin is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control:

    • in adults inadequately controlled on their maximally tolerated dose of metformin alone;
    • in adults inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;
    • in adults already being treated with the combination of empagliflozin and metformin as separate tablets.

    In the United States it is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

    Society and culture

    Legal status

    Empagliflozin/metformin was approved for use in the European Union in May 2015.

    Empagliflozin/metformin was approved for use in the United States in August 2015. The extended release version was approved for use in the United States in December 2016.

    Empagliflozin/metformin was approved for use in Australia in May 2020.

    External links



    Новое сообщение